Recent Advances in Ligand Design Methods

Reviews in Computational Chemistry

Volumn 11, Issue , 1997, Pages 1-66

  Murcko, Mark A ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0031491262     PISSN: 10693599     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (177)

1. F. Ni and H. A. Scheraga, Acc. Chem. Res., 27, 257 (1994). Use of the Transferred Nuclear Overhauser Effect to Determine the Conformations of Ligands Bound to Proteins.
2. G. Wagner, Curr. Opin. Struct. Biol., 3, 748 (1993). NMR Relaxation and Protein Mobility.
3. G. Wagner, J. Biomol. NMR, 3, 375 (1993). Prospects for NMR of Large Proteins.
4. A. G. Palmer III, Curr. Opin. Biotechol., 4, 385 (1993). Dynamic Properties of Proteins from NMR Spectroscopy.
5. A. Bax and S. Grzesiek, Acc. Chem. Res., 26, 131 (1993). Methodological Advances in Protein NMR.
6. S. W. Fesik, J. Med. Chem., 34, 2937 (1991). NMR Studies of Molecular Complexes as a Tool in Drug Design.
7. G. M. Clore and A. M. Gronenborn, Science, 252, 1390 (1991). Structures of Larger Proteins in Solution: Three- and Four-Dimensional Heteronuclear NMR Sspectroscopy.
8. J. L. Markley, Methods Enzymol., 176, 12 (1989). Two-Dimensional Nuclear Magnetic Resonance Spectroscopy of Proteins: An Overview.
9. A. T. Brunger, Nature, 355, 472 (1992). Free R Value: A Novel Statistical Quantity for Assessing the Accuracy of Crystal Structures.
10. A. T. Brunger, J. Kuriyan, and M. Karplus, Science, 235, 458 (1987). Crystallographic R Factor Refinement by Molecular Dynamics.
11. A. Kidera and N. Go, J. Mol. Biol., 225, 457 (1992). Normal Mode Refinement: Crystallographic Refinement of Protein Dynamic Structure.
12. S. Subbiah, Science, 252, 128 (1991). Low-Resolution Real-Space Envelopes: An Approach to the Ab Initio Macromolecular Phase Problem.
13. P. A. Karplus and C. Faerman, Curr. Opin. Struct. Biol. 4, 770 (1994). Ordered Water in Macromolecular Structure.
14. W. Kühlbrandt, Q. Rev. Biophys., 25, 1 (1992). Two-Dimensional Crystallization of Membrane Proteins.
15. A. C. W. May and T. L. Blundell, Curr. Biol., 5, 355 (1994). Automated Comparative Modelling of Protein Structures.
16. M. S. Johnson, N. Srinivasan, R. Sowdhamini, and T. L. Blundell, CRC Crit. Rev. Biochem. Mol. Biol., 29, 1 (1994). Knowledge-Based Protein Modelling.
17. J. S. Fetrow and S. H. Bryant, Bio/Technology, 11, 479 (1993). New Programs for Protein Tertiary Structure Prediction.
18. J. Bajorath, R. Stenkamp, and A. Aruffo, Protein Sci., 2, 1798 (1993). Knowledge-Based Model Building of Proteins: Concepts and Examples.
19. C. Sander and R. Schneider, Proteins: Struct., Funct., Genet., 9, 56 (1991). Database of Homology-Derived Protein Structures and the Structural Meaning of Sequence Alignment.
20. T. L. Blundell, B. L. Sibanda, M. J. E. Sternberg, and J. M. Thornton, Nature, 326, 347 (1987). Knowledge-Based Prediction of Protein Structures and the Design of Novel Molecules.
21. H. Kubinyi, Ed., 3D QSAR in Drug Design: Theory, Methods and Applications, ESCOM, Leiden, 1993. See also, T. I. Oprea and C. L. Waller, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., Wiley-VCH, New York, 1997, Vol. 11, pp. 127-181. Theoretical and Practical Aspects of Three-Dimensional Quantitative Structure - Activity Relationships. G. Greco, E. Novellino, and Y. C. Martin in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., Wiley-VCH, New York, 1997, Vol. 11, pp. 183-240. Approaches to Three-Dimensional Quantitative Structure-Activity Relationships.
22. H. Kubinyi, Ed., 3D QSAR in Drug Design: Theory, Methods and Applications, ESCOM, Leiden, 1993. See also, T. I. Oprea and C. L. Waller, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., Wiley-VCH, New York, 1997, Vol. 11, pp. 127-181. Theoretical and Practical Aspects of Three-Dimensional Quantitative Structure - Activity Relationships. G. Greco, E. Novellino, and Y. C. Martin in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., Wiley-VCH, New York, 1997, Vol. 11, pp. 183-240. Approaches to Three-Dimensional Quantitative Structure-Activity Relationships.
23. H. Kubinyi, Ed., 3D QSAR in Drug Design: Theory, Methods and Applications, ESCOM, Leiden, 1993. See also, T. I. Oprea and C. L. Waller, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., Wiley-VCH, New York, 1997, Vol. 11, pp. 127-181. Theoretical and Practical Aspects of Three-Dimensional Quantitative Structure - Activity Relationships. G. Greco, E. Novellino, and Y. C. Martin in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., Wiley-VCH, New York, 1997, Vol. 11, pp. 183-240. Approaches to Three-Dimensional Quantitative Structure-Activity Relationships.
24. M. A. Hahn, J. Med. Chem., 38, 2080 (1995). Receptor Surface Models. 1. Definition and Construction. M. A. Hahn and D. Rogers, J. Med. Chem., 38, 2091 (1995). Receptor Surface Models. 2. Application to Quantitative Structure Activity Relationship Studies.
25. M. A. Hahn, J. Med. Chem., 38, 2080 (1995). Receptor Surface Models. 1. Definition and Construction. M. A. Hahn and D. Rogers, J. Med. Chem., 38, 2091 (1995). Receptor Surface Models. 2. Application to Quantitative Structure Activity Relationship Studies.
26. N. C. Cohen, J. M. Blaney, C. Humblet, P. Gund, and D. C. Barry, J. Med. Chem., 33, 883 (1990). Molecular Modeling Software and Methods for Medicinal Chemistry.
27. M. A. Navia and M. A. Murcko, Curr. Opin. Struct. Biol., 2, 202 (1992). The Use of Structural Information in Drug Design.
28. L. M. Balbes, S. W. Mascarella, and D. B. Boyd, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH, New York, 1994, Vol. 5, pp. 337-380. A Perspective of Modern Methods in Computer-Aided Drug Design.
29. P. J. Whittle and T. L. Blundell, Annu. Rev. Biophys. Biomol. Struct., 23, 349 (1994). Protein Structure-Based Drug Design.
30. W. C. Guida, Curr. Opin. Struct. Biol., 4, 777 (1994). Software for Structure-Based Drug Design.
31. M. D. Walkinshaw, Med. Res. Rev., 12, 317 (1992). Protein Targets for Structure-Based Drug Design.
32. P. M. Colman, Curr. Opin. Struct. Biol., 4, 868 (1994). Structure-Based Drug Design.
33. J. Greer, J. W. Erickson, J. J. Baldwin, and M. D. Varney, J. Med. Chem., 37, 1035 (1994). Application of the Three-Dimensional Structures of Protein Target Molecules in Structure-Based Drug Design.
34. J. J. Baldwin, G. S. Ponticello, P. S. Anderson, M. E. Christy, M. A. Murcko, W. C. Randall, H. Schwam, M. F. Sugrue, J. P. Springer, P. Gautheron, J. Grove, P. Mallorga, M.-P. Viader, B. M. McKeever, and M. A. Navia, J. Med. Chem., 32, 2510 (1989). Thienothiopyran-2-sulfonamides: Novel Topically Active Carbonic Anhydrase Inhibitors for the Treatment of Glaucoma.
35. K. Appelt, R. J. Bacquet, C. A. Barlett, C. L. J. Booth, S. T. Freer, M. A. Fuhry, M. R. Gehring, S. M. Hermann, E. F. Howland, C. A. Janson, T. R. Jones, C.-C. Kan, V. Kathardekar, K. K. Lewis, G. P. Marzoni, D. A. Matthews, C. Mohr, E. W. Moomaw, C. A. Morse, S. J. Oatley, R. C. Ogden, M. R. Reddy, S. H. Reich, W. S. Schoettlin, W. W. Smith, M. D. Varney, J. E. Villafranca, R. W. Ward, S. Webber, S. E. Webber, K. Welsh, and J. White, J. Med. Chem., 34, 1925 (1991). Design of Enzyme Inhibitors Using Iterative Protein Crystallographic Analysis.
36. J. A. Montgomery, S. Niwas, J. D. Rose, J. A. Secrist III, Y. S. Babu, C. E. Bugg, M. D. Erion, W. C. Guida, and S. E. Ealick, J. Med. Chem., 36, 55 (1993). Structure-Based Design of Inhibitors of Purine Nucleoside Phosphorylase. 1. 9-(Arylmethyl) Derivatives of 9-Deazaguanine.
37. 2 Symmetric Inhibitor Complexed to HIV-1 Protease.
38. P. Y. S. Lam, P. K. Jadhav, C. J. Eyermann, C. N. Hodge, Y. Ru, L. T. Bacheler, J. L. Meek, M. J. Otto, M. M. Rayner, Y. N. Wong, C.-H. Chang, P. C. Weber, D. A. Jackson, T. R. Sharpe, and S. Erickson-Viitanen, Science, 263, 380 (1994). Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors.
39. M. von Itzstein, W. Y. Wu, G. B. Kok, M. S. Pegg, J. C. Dyason, B. Jin, T. Van Phan, M. L. Smythe, H. F. White, S. W. Oliver, P. M. Colman, J. N. Varghese, D. M. Ryan, J. M. Woods, R. C. Bethell, V. J. Hotham, J. M. Cameron, and C. R. Penn, Nature, 363, 418 (1993). Rational Design of Potent Sialidase-Based Inhibitors of Influenza Virus Replication.
40. E. E. Kim, C. T. Baker, M. D. Dwyer, M. A. Murcko, B. G. Rao, R. D. Tung, and M. A. Navia, J. Am. Chem. Soc., 117, 1181 (1995). Crystal-Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme.
41. R. S. Bohacek, C. McMartin, and W. C. Guida, Med. Chem. Rev., 16, 3 (1996). The Art and Practice of Structure-Based Drug Design: A Molecular Modeling Perspective.
42. P. S. Charifson and I. D. Kuntz, in Practical Applications of Computer-Aided Drug Design, P. S. Charifson, Ed., Dekker, New York, 1997, pp. 1-37. Recent Successes and Continuing Limitations in Computer-Aided Drug Design.
43. H.-J. Böhm, in 3D-QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp.386-405. Ligand Design.
44. R. A. Lewis and A. R. Leach, J. Comput.-Aided Mol. Design, 8, 467 (1994). Current Methods for Site-Directed Structure Generation.
45. D. E. Clark, C. W. Murray, and J. Li, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., Wiley-VCH, New York, 1997, Vol. 11, pp. 67-125. Current Issues in De Novo Molecular Design.
46. M. A. Murcko, in Practical Applications of Computer-Aided Drug Design, P. S. Charifson, Ed., Dekker, New York, 1997, pp. 305-354. An Introduction to De Novo Ligand Design.
47. Ajay and M. A. Murcko, J. Med. Chem., 38, 4953 (1995). Computational Methods to Predict Binding Free Energy in Ligand-Receptor Complexes.
48. Ajay, P. F. Stouten, and M. A. Murcko, in Practical Applications of Computer-Aided Drug Design, P. S. Charifson, Ed., Dekker, New York, 1997, pp. 355-410. The Prediction of Ligand Binding Energies.
49. P. J. Goodford, J. Med. Chem., 28, 849 (1985). A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules.
50. D. N. A. Boobbyer, P. J. Goodford, P. M. McWhinnie, and R. C. Wade, J. Med. Chem., 32, 1083 (1989). New Hydrogen-Bond Potentials for Use in Determining Energetically Favorable Binding Sites in Molecules of Known Structure.
51. R. C. Wade, K. J. Clark, and P. J. Goodford, J. Med. Chem., 36, 140 (1993). Further Development of Hydrogen Bond Functions for Use in Determining Energetically Favorable Binding Sites on Molecules of Known Structure. I. Ligand Probe Groups with the Ability to Form Two Hydrogen Bonds.
52. R. C. Wade and P. J. Goodford, J. Med. Chem., 36, 148 (1993). Further Development of Hydrogen Bond Functions for Use in Determining Energetically Favorable Binding Sites on Molecules of Known Structure. 2. Ligand Probe Groups with the Ability to Form More than Two Hydrogen Bonds.
53. R. C. Wade, in 3D-QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 486-505. Molecular Interaction Fields.
54. 2 Inhibitors.
55. 2 Inhibitor Leading to Enhanced Activity.
56. V. Helms, E. Deprez, E. Gill, C. Barret, G. Hui Bon Hoa, and R. C. Wade, Biochemistry, 35, 1485 (1996). Improved Binding of Cytochrome P450cam Substrate Analogs Designed to Fill Extra Space in the Substrate Binding Pocket.
57. N. Tomioka, A. Itai, and Y. Iitaka, J. Comput.-Aided Mol. Design, 1, 197 (1987). A Method for Fast Energy Estimation and Visualization of Protein-Ligand Interactions.
58. N. Tomioka, A. Itai, and Y. Iitaka, in Three-Dimensional Structures and Drug Action, Y. Iitaka and A. Itai, Eds., University of Tokyo Press, Tokyo, 1987, pp. 186-194. Real-Time Estimation and Visualization of Protein - Ligand Interaction on 3D Graphics Display.
59. N. Tomioka and A. Itai, J. Comput.-Aided Mol. Design, 8, 347 (1994). GREEN: A Program Package for Docking Studies in Rational Drug Design.
60. D. J. Dansiger and P. M. Dean, Proc. R. Soc. London, B236, 101 (1989). Automated Site-Directed Drug Design: A General Algorithm for Knowledge Acquisition About HydrogenBonding Regions at Protein Surfaces.
61. D. J. Dansiger and P. M. Dean, Proc. R. Soc. London, B236, 115 (1989). Automatic Site-Directed Drug Design: The Prediction and Observation of Ligand Point Positions at Hydrogen-Bonding Regions on Protein Surfaces.
62. E. N. Baker and R. E. Hubbard, Prog. Biophys. Mol. Biol., 44, 97 (1984). Hydrogen Bonding in Globular Proteins.
63. C. S. Poornima and P. M. Dean, J. Comput.-Aided Mol. Design, 9, 500 (1995). Hydration in Drug Design. 1. Multiple Hydrogen-Bonding Features of Water Molecules in Mediating Protein-Ligand Interactions.
64. C. S. Poornima and P. M. Dean, J. Comput.-Aided Mol. Design, 9, 513 (1995). Hydration in Drug Design. 2. Influence of Local Site Surface Shape on Water Binding.
65. C. S. Poornima and P. M. Dean, J. Comput.-Aided Mol. Design, 9, 521 (1995). Hydration in Drug Design. 3. Conserved Water Molecules at the Ligand-Binding Sites of Homologous Proteins.
66. A. Miranker and M. Karplus, Proteins: Struct., Funct., Genet., 11, 29 (1991). Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method.
67. A. Caflisch, A. Miranker, and M. Karplus, J. Med. Chem., 36, 2142 (1993). Multiple Copy Simultaneous Search and Construction of Ligands in Binding Sites: Applications to Inhibitors of HIV-1 Aspartic Proteinase.
68. T. N. Hart and R. J. Read, Proteins: Struct., Funct., Genet., 13, 206 (1992). A Multiple-Start Monte-Carlo Docking Method.
69. S.-Y. Yue, Protein Eng., 4, 177 (1990). Distance-Constrained Molecular Docking by Simulated Annealing.
70. S. R. Wilson and F. Guarneri, Tetrahedron Lett., 32, 3601 (1991). Calculation of Rotational States of Flexible Molecules Using Simulated Annealing.
71. F. Guarnieri and W. C. Still, J. Comput. Chem., 15, 1302 (1994). A Rapidly Convergent Simulation Method: Mixed Monte Carlo/Stochastic Dynamics.
72. A. Caflisch, P. Niederer, and M. Anliker, Proteins: Struct., Fund., Genet., 13, 223 (1992). Monte Carlo Docking of Oligopeptides to Proteins.
73. Z. Li and H. A. Scheraga, Proc. Natl. Acad. Sci. USA, 84, 6611 (1987). Monte-Carlo Minimization Approach to the Multiple-Minima Problem in Protein Folding.
74. D. J. Abraham and G. E. Kellogg, in 3D-QSAR in Drug Design, H. Kubinyi, Ed., ESCOM, 1993, pp. 506-522. Hydrophobic Fields.
75. G. E. Kellogg, S. F. Semus, and D. J. Abraham, J. Comput.-Aided Mol. Design, 5, 545 (1991). HINT: A New Method of Empirical Hydrophobic Field Calculation for CoMFA. G. E. Kellogg, G. S. Joshi, and D. J. Abraham, Med. Chem. Res., 1, 444 (1992). New Tools for Modeling and Understanding Hydrophobicity and Hydrophobic Interactions.
76. G. E. Kellogg, S. F. Semus, and D. J. Abraham, J. Comput.-Aided Mol. Design, 5, 545 (1991). HINT: A New Method of Empirical Hydrophobic Field Calculation for CoMFA. G. E. Kellogg, G. S. Joshi, and D. J. Abraham, Med. Chem. Res., 1, 444 (1992). New Tools for Modeling and Understanding Hydrophobicity and Hydrophobic Interactions.
77. F. C. Wireko, G. E. Kellogg, and D. J. Abraham, J. Med. Chem., 34, 758 (1991). Allosteric Modifiers of Hemoglobin. 2. Crystallographicallly Determined Binding Sites and Hydrophobic Binding/Interaction Analysis of Novel Hemoglobin Oxygen Effectors.
78. D. J. Abraham and G. E. Kellogg, J. Comput.-Aided Mol. Design, 8, 41 (1994). The Effect of Physical Organic Properties on Hydrophobic Fields. See also references therein.
79. See also, P.-A. Carrupt, B. Testa, and P. Gaillard, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., Wiley-VCH, New York, 1997, Vol. 11, pp. 241-315. Computational Approaches to Lipophilicity: Methods and Applications.
80. S. H. Rotstein and M. A. Murcko, J. Med. Chem., 36, 1700 (1993). GroupBuild: A Fragment-Based Method for De Novo Drug Design.
81. F. C. Bernstein, T. F. Koetzle, G. J. B. Williams, E. F. Meyer, M. D. Brice, J. R. Rodgers, O. Kennard, T. Shimanouchi, and M. Tisumi, J. Mol. Biol., 112, 535 (1977). The Protein Data Bank: A Computer-Based Archival File for Macromolecular Structures.
82. F. H. Allen, O. Kennard, and R. Taylor, Acc. Chem. Res., 16, 146 (1983). Systematic Analysis of Structural Data as a Research Technique in Organic Chemistry.
83. D. Ringe, Curr. Opin. Struct. Biol., 5, 825 (1995). What Makes a Binding Site a Binding Site?
84. M. C. Lawrence and P. C. Davis, Proteins: Struct., Funct., Genet., 12, 31 (1992). CLIX: A Search Algorithm for Finding Novel Ligands Capable of Binding Proteins of Known Three-Dimensional Structure.
85. H.-J. Böhm, J. Comput.-Aided Mol. Design. 6, 61 (1992). The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors.
86. H.-J. Böhm, J. Comput.-Aided Mol. Design, 6, 593 (1992). Rule-Based Automatic Design of New Substituents for Enzyme Inhibitor Leads.
87. R. E. Babine, T. M. Bleckman, C. R. Kissinger, R. Showalter, L. A. Pelletier, C. Lewis, K. Tucker, E. Moomaw, H. E. Parge, and J. E. Villafranca, Bioorg. Med. Chem. Lett., 5, 1719 (1995). Design, Synthesis, and X-Ray Crystallographic Studies of Novel FKBP12 Ligands.
88. C. L. M. J. Verlinde, G. Rudenko, and W. G. J. Hol, J. Comput.-Aided Mol. Design, 6, 131 (1992). Search of New Lead Compounds for Trypanosomiasis Drug Design: A Protein Structure-Based Linked-Eragment Approach.
89. G. Klebe, J. Mol. Biol., 237, 212 (1994). The Use of Composite Crystal-Field Environments in Molecular Recognition and the De Novo Design of Protein Ligands.
90. G. M. Downs and P. Willett, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH Publishers, New York, 1995, Vol. 7, pp. 1-66. Similarity Searching in Databases of Chemical Structures.
91. A. C. Good and J. S. Mason, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH Publishers, New York, 1995, Vol. 7, pp. 67-118. Three-Dimensional Structure Searches.
92. R. A. Lewis and P. M. Dean, Proc. R. Soc. London, B236, 125 (1989). Automated Site-Directed Drug Design: The Concept of Spacer Skeletons for Primary Structure Generation.
93. R. A. Lewis and P. M. Dean, Proc. R. Soc. London. B236, 141 (1989). Automated Site-Directed Drug Design: The Formation of Molecular Templates in Primary Structure Generation.
94. R. A. Lewis, J. Comput.-Aided Mol. Design, 4, 205 (1990). Automated Site-Directed Drug Design: Approaches to the Formation of 3D Molecular Graphs.
95. R. A. Lewis, D. C. Roe, C. Huang, T. E. Ferrin, R. Langridge, and J. D. Kuntz, J. Mol. Graphics, 10, 66 (1992). Automated Site-Directed Drug Design Using Molecular Lattices.
96. R. A. Lewis, J. Mol. Graphics, 10, 131 (1992). Automated Site-Directed Drug Design: A Method for the Generation of General 3D Molecular Graphs.
97. S. R. Kilvington and A. R. Leach, Molecular Graphics Society Meeting, University of York, UK, March 28, 1993. An Algorithm for Connecting Docked Fragments.
98. A. R. Leach and R. A. Lewis, J. Comput. Chem., 15, 233 (1994). A Ring-Bracing Approach to Computer-Assisted Ligand Design.
99. T. E. Ferrin, C. C. Huang, L. E. Jarvis, and R. Langridge, J. Mol. Graphics, 6, 13 (1988). The Midas Display System.
100. P. S. Shenkin, D. L. Yarmush, R. M. Fine, H. Wang, and C. Levinthal, Biopolymers, 26, 2053 (1987). Predicting Antibody Hypervariable Loop Conformation. 1. Ensembles of Random Conformations for Ringlike Structures.
101. P. A. Bartlett, G. T. Shea, S. J. Telfer, and S. Waterman, in Molecular Recognition in Chemical and Biological Problems, Special Publication of the Royal Chemical Society, 78, 182 (1989). CAVEAT: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules.
102. G. Lauri and P. A. Bartlett, J. Comput.-Aided Mol. Design, 8, 51 (1994). CAVEAT: A Program to Facilitate the Design of Organic Molecules.
103. M. B. Eisen, D. C. Wiley, M. Karplus, and R. E. Hubbard, Proteins: Struct., Funct., Genet., 19, 199 (1994). HOOK: A Program for Finding Novel Molecular Architectures That Satisfy the Chemical and Steric Requirements of a Macromolecule Binding Site.
104. C. M. Ho and G. R. Marshall, J. Comput-Aided Mol. Design, 7, 623 (1993). SPLICE: A Program to Assemble Partial Query Solutions from Three-Dimensional Database Searches into Novel Ligands.
105. C. M. Ho and G. R. Marshall, J. Comput.-Aided Mol. Design, 7, 3 (1993). FOUNDATION: A Program to Retrieve All Possible Structures Containing a User-Defined Minimum Number of Matching Query Elements from Three-Dimensional Databases.
106. C. M. W. Ho and G. R. Marshall, Proceedings of the 27th Hawaiian International Conference on Systems Sciences, Biotechnology Computing, IEEE Computer Society Press, Los Alamitos, CA, 1994, Vol. 5, pp. 213-222. De Novo Design of Ligands.
107. C. M. W. Ho and G. R. Marshall, J. Comput.-Aided Mol. Design, 9, 65 (1995). DBMAKER: A Set of Programs Designed to Generate Three-Dimensional Databases Based upon User-Specified Criteria.
108. C. M. W. Ho and G. R. Marshall, J. Comput.-Aided Mol. Design, 4, 337 (1990). Cavity Search: An Algorithm for the Isolation and Display of Cavity-Like Binding Regions.
109. V. Tschinke and N. C. Cohen, J. Med. Chem., 36, 3863 (1993). The NEWLEAD Program: A New Method for the Design of Candidate Structures from Pharmacophoric Hypotheses.
110. D. E. Clark, D. Frenkel, S. A. Levy, J. Li, C. W. Murray, B. Robson, B. Waszkowycz, and D. R. Westhead, J. Comput.-Aided Mol. Design, 9, 13 (1995). PRO_LIGAND: An Approach to De Novo Drug Design. 1. Application to the Design of Organic Molecules.
111. B. Waszkowcycz, D. E. Clark, D. Frenkel, J. Li, C. W. Murray, B. Robson, and D. R. Westhead, J. Med. Chem., 37, 3994 (1994). PRO_LIGAND: An Approach to De Novo Molecular Design. 2. Design of Novel Molecules from Molecular Field Analysis (MFA) Models and Pharmacophores.
112. P. W. Rose, Abstracts of the 207th American Chemical Society National Meeting, March 13-18, 1994, San Diego, CA, COMP 50. Exhaustive Search for Molecular Linkers in Structure-Based Drug Design.
113. A. A. Cohen and S. E. Shatzmiller, J. Mol. Graphics, 11, 166 (1993). Structure Design: An Artificial Intelligence-Based Method for the Design of Molecules Under Geometrical Constraints.
114. R. P. Sheridan, A. Rusinko III, R. Nilakantan, and R. Venkataraghavan, Proc. Natl. Acad. Sci. USA, 86, 8165 (1989). Searching for Pharmacophores in Large Coordinate Databases and Its Use in Drug Design.
115. J. H. Van Drie, D. Weininger, and Y. C. Martin, J. Comput.-Aided Mol. Design, 3, 225 (1989). ALADDIN: An Integrated Tool for Computer-Assisted Molecular Design and Pharmacophore Recognition from Geometric, Steric, and Substructure Searching of Three-Dimensional Molecular Structures.
116. S. E. Jakes and P. Willen, J. Mol. Graphics, 4, 12 (1986). Pharmacophoric Pattern Matching in Files of 3-D Chemical Structures: Selection of Interatomic Distance Screens.
117. Y. C. Martin, J. Med. Chem., 35, 2145 (1992). 3D Database Searching in Drug Design.
118. Y. C. Martin, M. G. Bures, and P. Willett, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH Publishers, New York, 1990, Vol. 1, pp. 213-264. Searching Databases of Three-Dimensional Structure.
119. The Available Chemicals Directory (ACD) and a variety of other 3D chemical databases are available from MDL Information Systems (Reed Elsevier), 14600 Catalina Street, San Leandro, CA 94577. Also, see the Appendix of the present volume.
120. Y. Nishibata and A. Itai, Tetrahedron, 47, 8985 (1991). Automatic Creation of Drug Candidate Structures Based on Receptor Structure - Starting Point for Artificial Lead Generation.
121. Y. Nishibata and A. Itai, J. Med. Chem., 36, 2921 (1993). Confirmation of Usefulness of a Structure Construction Program Based on Three-Dimensional Receptor Structure for Rational Lead Generation.
122. S. H. Rotstein and M. A. Murcko, J. Comput.-Aided Mol. Design, 7, 23 (1993). GenStar 1.0: A Method for De Novo Drug Design.
123. R. S. Bohacek and C. McMartin, J. Am. Chem. Soc., 116, 5560 (1994). Multiple Highly Diverse Structures Complementary to Enzyme Binding Sites: Results of Extensive Application of a De Novo Design Method Incorporating Combinatorial Growth.
124. J. B. Moon and W. J. Howe, Proteins: Struct., Funct., Genet., 11, 314 (1991). Computer Design of Bioactive Molecules: A Method for Receptor-Based De Novo Ligand Design.
125. J. B. Moon and W. J. Howe, in Trends in QSAR Molecules Modelling 1992, C.-G. Wermuth, Ed., ESCOM, Leiden, 1993, pp. 11-19. Recent Advances in De Novo Molecular Design.
126. J. B. Moon and W. J. Howe, American Crystallographic Society/Molecular Graphics Society Meeting, Albuquerque, NM, May 1993. Automated Receptor-Based Ligand Design: Development of the GROW Program.
127. K. D. Gibson and H. A. Scheraga, J. Comput. Chem., 8, 826 (1987). Revised Algorithms for the Build-up Procedure for Predicting Protein Conformations by Energy Minimization.
128. J. Singh, J. Saldanha, and J. M. Thornton, Protein Eng., 4, 251 (1991). A Novel Method for the Modeling of Peptide Ligands to Their Receptors.
129. V. Gillet, A. P. Johnson, P. Mata, S. Sike, and P. Williams, J. Comput.-Aided Mol. Design, 7, 127 (1993). SPROUT: A Program for Structure Generation.
130. V. J. Gillet W. Newell, P. Mata, G. Myatt, S. Sike, Z. Zsoldos, and A. P. Johnson, J. Chem. Inf. Comput. Sci., 34, 207 (1994). SPROUT: Recent Developments in the De Novo Design of Molecules.
131. V. J. Gillet, G. Myatt, Z. Zsoldos, and A. P. Johnson, in Perspectives in Drug Discovery and Design, K. Müller, Ed., ESCOM, Leiden, 1995, Vol. 3, pp. 34-50. SPROUT, HIPPO, and CAESA: Tools for De Novo Structure Generation and Estimation of Synthetic Accessibility.
132. LEAPFROG manual, SYBYL version 6.1, Tripos Associates, St. Louis, MO.
133. T. P. Lybrand, Curr. Opin. Struct. Biol. 5, 224 (1995). Ligand - Protem Docking and Rational Drug Design.
134. G. Jones and P. Willett, Curr. Opin. Biotechnol., 6, 652 (1995). Docking Small-Molecule Ligands into Active Sites.
135. I. D. Kuntz, J. M. Blaney, S. J. Oatley, R. Langridge, and T. E. Ferrin, J. Mol. Biol., 161, 269 (1982). A Geometric Approach to Macromolecule - Ligand Interactions.
136. R. L. DesJarlais, G. L. Seibel, I. D. Kuntz, P. S. Furth, J. C. Alvarez, P. R. O. De Montellano, D. L. DeCamp, L. M. Babé, and C. S. Craik, Prof. Natl. Acad. Sci. USA, 87, 6644 (1990). Structure-Based Design of Nonpeptide Inhibitors Specific for the Human Immunodeficiency Virus 1 Protease.
137. R. L. DesJarlais, R. P. Sheridan, G. L. Seibel, J. S. Dixon, I. D. Kuntz, and R. Venkataraghavan, J. Med. Chem., 31, 722 (1989). Using Shape Complementarity as an Initia Screen in Designing Ligands for a Receptor Binding Site of Known Three-Dimensional Structure.
138. E. C. Meng, D. A. Gschwend, J. M. Blaney, and I. D. Kuntz, Proteins, 7, 266 (1993). Orientational Sampling and Rigid-Body Minimization in Molecular Docking.
139. E. C. Meng, B. K. Shoichet, and I. D. Kuntz, J. Comput. Chem., 13, 505 (1992). Automated Docking with Grid-Based Energy Evaluation.
140. R. L. DesJarlais and J. S. Dixon, J. Comput.-Aided Mol. Design, 8, 231 (1994). A Shape- and Chemistry-Based Docking Method and Its Use in the Design of HIV-1 Protease Inhibitors.
141. B. K. Shoichet and I. D. Kuntz, Protein Eng., 6, 723 (1993). Matching Chemistry and Shape in Molecular Docking.
142. D. L. Bodian, R. B. Yamasaki, R. L. Buswell, J. F. Stearns, J. M. White, and I. D. Kuntz, Biochemistry, 32, 2967 (1993). Inhibition of the Fusion-Inducing Conformational Change of Influenza Hemagglutinin by Benzoquinones and Hydroquinones.
143. C. S. Ring, E. Sun, J. H. McKerrow, G. K. Lee, P. J. Rosenthal, I. D. Kuntz, and F. E. Cohen, Proc. Natl. Acad. Sci. USA, 90, 3583 (1993). Structure-Based Inhibitor Design by Using Protein Models for the Development of Antiparasitic Agents.
144. R. L. DesJarlais, R. P. Sheridan, J. S. Dixon, I. D. Kuntz, and R. Venkataraghavan, J. Med. Chem., 29, 2149 (1986). Docking Flexible Ligands to Macromolecular Receptors by Molecular Shape.
145. A. R. Leach and I. D. Kuntz, J. Comput. Chem., 13, 730 (1992). Conformational Analysis of Flexible Ligands in Macromolecular Receptor Sites.
146. S. K. Kearsley, D. J. Underwood, R. P. Sheridan, and M. D. Miller, J. Comput.-Aided Mol. Design, 8, 565 (1994). FlexiBases: A Way to Enhance the Use of Molecular Docking Methods.
147. M. D. Miller, S. K. Kearsley, D. J. Underwood, and R. P. Sheridan, J. Comput.-Aided Mol. Design, 8, 8153 (1994). FLOG: A System to Select Quasi-Flexible Ligands Complementary to a Receptor of Known Three-Dimensional Structure.
148. W. P. Walters, M. R Stahl, and D. Dolata, J. Chem. Inf. Comput. Sci., submitted for publication. WIZARD III: A Program for Fast Conformation Generation.
149. W. P. Walters, Abstracts of the 211th American Chemical Society National Meeting, New Orleans, LA, March 24-28, 1996, CINF 50. Developing an Integrated Set of Tools for Identifying Potential Drug Candidates.
150. G. Klebe and T. Mietzner, J. Comput.-Aided Mol. Design, 8, 583 (1994). A Fast and Efficient Method to Generate Biologically Relevant Conformations.
151. D. J. Bacon and J. Moult, J. Mol. Biol., 225, 849 (1992). Docking by Least-Squares Fitting of Molecular Surface Patterns.
152. S. Sudarsanam, G. D. Virca, C. J. March, and S. Srinivasan, J. Comput.-Aided Mol. Design, 6, 223 (1992). An Approach to Computer-Aided Inhibitor Design: Application to Cathepsin L.
153. D. S. Goodsell and A. J. Olsen, Proteins: Struct., Funct., Genet., 8, 195 (1990). Automated Docking of Substrates to Proteins by Simulated Annealing.
154. D. S. Goodsell, H. Lauble, C. D. Stout, and A. J. Olson, Proteins: Struct., Funct., Genet., 17, 1 (1993). Automated Docking in Crystallography: Analysis of the Substrates of Aconitase.
155. J. M. Blaney, Abstracts of the American Chemical Society National Meeting, Symposium on 3D Chemical Structure Handling, New York, August 28, 1991. A Distance Geometry-Based Approach for Docking Conformationally Flexible Molecules from 2D or 3D-Chemical Databases.
156. J. M. Blaney and J. S. Dixon, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH Publishers, New York, 1994, Vol. 5, pp. 299-335. Distance Geometry in Molecular Modeling.
157. K. P. Clark and Ajay, J. Comput. Chem., 16, 1210 (1995). Flexible Ligand Docking Without Parameter Adjustment Across Four Ligand - Receptor Complexes.
158. R. S. Judson, Y. T. Tan, E. Mori, C. Melius, E. P. Jaeger, A. M. Treasurywala, and A. Mathiowetz, J. Comput. Chem., 16, 1405 (1995). Docking Flexible Molecules: A Case Study of Three Proteins.
159. C. M. Oshiro, I. D. Kuntz, and J. S. Dixon, J. Comput.-Aided Mol. Design, 9, 113 (1995). Flexible Ligand Docking Using a Genetic Algorithm.
160. G. Jones, P. Willett, and R. C. Glen, J. Mol. Biol., 245, 43 (1995). Molecular Recognition of Receptor-Sites Using a Genetic Algorothm with a Description of Desolvation.
161. D. K. Gehlhaar, G. M. Verkhivker, P. A. Rejto, C. J. Sherman, D. B. Fogel, L. J. Fogel, and S. T. Freer, Chem. Biol., 2, 317 (1995). Molecular Recogniton of the Inhibitor AG-1343 by HIV-1 Protease - Conformationally Flexible Docking by Evolutionary Programming.
162. A. W. Payne and R. C. Glen, J. Mol. Graphics, 11, 74 (1993). Molecular Recognition Using a Binary Genetic Search Algorithm.
163. J. M. Blaney, D. Weininger, and J. S. Dixon, Molecular Graphics Society Meeting, University of York, UK, March 28, 1993. Conformationally Flexible Docking and Evolution of Molecules to Fit a Binding Site of Known Structure.
164. D. A. Pearlman and M. A. Murcko, J. Comput. Chem., 14, 1184 (1993). CONCEPTS: New Dynamic Algorithm for De Novo Drug Suggestion.
165. D. A. Pearlman and M. A. Murcko, J. Med. Chem., 39, 1651 (1996). CONCERTS: Dynamic Connection of Fragments as an Approach to De Novo Ligand Design.
166. A. Miranker and M. Karplus, Molecular Graphics Society Meeting, University of York, UK, March 28, 1993. Ligand Perturbation Space: An Algorithm for De Novo Ligand Design.
167. A. Miranker and M. Karplus, Proteins: Struct., Funct., Genet., 23, 472 (1995). An Automated-Method for Dynamic Ligand Design.
168. D. K. Gehlhaar, K. E. Moerder, D. Zichi, C. J. Sherman, R. C. Ogden, and S. T. Freer, J. Med. Chem., 38, 466 (1995). De Novo Design of Enzyme Inhibitors by Monte Carlo Ligand Generation.
169. M. A. Hahn, Abstracts of the American Chemical Society National Meeting, April 2-6, 1995, Anaheim, CA, COMP 107. Receptor Surface Models as a Guide to Drug Discovery.
170. R. Judson, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH Publishers, New York, 1997, Vol. 10, pp. 1-73. Genetic Algorithms and Their Use in Chemistry.
171. R. D. Cramer, D. E. Patterson, and J. D. Bunce, J. Am. Chem. Soc., 110, 5959 (1988). Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding of Steroids to Carrier Proteins.
172. R. S. Pearlman, in 3D-QSAR in Drug Design: Theory, Method and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 41-79. 3D Molecular Structures: Generation and Use in 3D Searching.
173. S. Y. S. Cho, L. N. Jungheim, and A. J. Baxter, Bioorg. Med. Chem. Lett., 5, 715 (1994). Novel HIV-1 Protease Inhibitors Containing a β-Hydroxy Sulfide Isostere.
174. R. C. Glen and A. W. R. Payne, J. Comput.-Aided. Mol. Design, 9, 181 (1995). A Genetic Algorithm for the Automated Generation of Molecules Within Constraints.
175. P. R. Connelly, R. A. Aldape, F. J. Bruzzese, S. P. Chambers, M. J. Fitzgibbon, M. A. Fleming, S. Itoh, D. J. Livingston, M. A. Navia, and J. A. Thomson, Proc. Natl. Acad. Sci. USA, 91, 1964 (1994). Enthalpy of Hydrogen Bond Formation in a Protein - Ligand Binding Reaction.
176. R. Hirschmann, Angew. Chem., Int. Ed. Engl., 30, 1278 (1991). Medicinal Chemistry in the Golden Age of Biology: Lessons from Steroid and Peptide Research.
177. M. A. Navia and P. R. Chaturvedi, Drug Discovery Today, 1, 179 (1996). Design Principles for Orally Bioavailable Drugs.